Supplementary Information

A new approach to construct full-length glycosylphosphatidylinositols of parasitic protozoa and [4-deoxy-Man-III]-GPI analogues

Asif Ali^a, D. Channe Gowda^b and Ram A. Vishwakarma^{*a}

 ^a Bio-organic Chemistry Laboratory, National Institute of Immunology, JNU Complex, New Delhi, India Fax: 91-11-26162125; Tel: 91-11-26717178; E-mail: ram@nii.res.in
^b Deparment of Biochemistry and Molecular Biology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA

General Experimental Procedures:

Solvents were purified according to the standard procedures, and reagents used were of highest purity available. All reactions were performed in flame-dried glass apparatus under argon atmosphere unless mentioned otherwise. Anhydrous solvents like CH₂Cl₂, Et₂O, THF, CH₃OH, CH₃CN, DMF, pyridine, Et₃N were freshly dried using standard methods. NMR measurements (¹H, ¹³C, ³¹P, 2D ¹H-¹H and ¹H-¹³C COSY, HMQC) were recorded on a 300 MHz spectrometer (Bruker) fitted with pulse-field gradient probe, and trimethylsilane (TMS) or residual resonance of deuterated solvent were used as internal reference. For ³¹P NMR spectra, phosphoric acid was used as external reference. ¹³C NMR spectra were broadband ¹H decoupled or inverse HMQC experiments. Chemical shifts are expressed in ppm and coupling constants J in Hz. Mass-spectra (ESI) and highresolution mass-spectra (HRMS) were obtained on quadrupole and LCT-TOF (time of flight) spectrometers respectively using acetonitrile-water (1:1) mobile phase. Optical rotations were measured on a digital Perkin-Elmer 241 polarimeter. Analytical TLC was performed on Merck Kieselgel 60 F254 plates, and compounds visualized by ammoniummolybdate/ceric-sulfate developing reagent. Preparative TLC was conducted on Analtech Uniplate silica-gel plates (20 x 20 cm). Silica column chromatography was carried out with silica gel 60 (60-120 mesh) or flash silica gel (230-400 mesh). Analytical and semipreparative HPLC purification were carried out on a Shimadzu system using RP-18 columns and a photodiode array detector system.

2,3,4,5-tetra-O-benzyl-1-O-(4-methoxybenzyl)-(DL)-myo-inositol (7). A solution of racemic 2,3:4,5-di-O-cyclohexylidene-myo-inositol (34 g, 100 mmol, prepared by a reported¹ method) and dibutyl tinoxide (24 g 93 mmol) in anhydrous CH₃OH (200 mL) was heated to reflux for 4 h. Excess of solvent was removed and the residue was dried by repeated evaporation through toluene. The residue was dissolved in anhyd DMF (150 mL) followed by the addition of pre-dried CsF (20 g, 120 mmol), KI (20 g, 120 mmol) and PMBCl (25 mL, 184 mmol). The suspension was vigorously stirred for 24 h at rt. The solvent was removed under reduced pressure and the residue was purified by silica column chromatography (85:15 to 70:30 hexane/EtOAc) to provide two known² regioisomers: 2,3:4,5-di-O-cyclohexylidene-6-O-(p-methoxybenzyl)-(DL)-myo-inositol (16 g, 38%, Rf = 0.43 in 20% EtOAc-hexane) and 2,3:4,5-di-O-cyclohexylidene-1-O-(pmethoxybenzyl)-(DL)-myo-inositol (18 g, 43%, Rf = 0.2 in 20% EtOAc-hexane). The desired more polar isomer (13.2 g, 28.6 mmol) was dissolved in anhyd DMF (250 mL) and solution was brought to 0 °C and then NaH (4.3 g) and allyl bromide (10 mL) were added. The reaction mixture was stirred for 3 h at room temperature and brine (500 mL) was added, and extracted with diethyl ether (250 mL x 4). The organic extract was dried over anhyd Na₂SO₄, concentrated and the residue was purified by a silica column to give 6-O-allyl-2,3,4,5-di-O-cyclohexylidene-1-O-(4-methoxybenzyl)-(DL)-myo-inositol (14)g, 99% yield). The above bis-ketal (14 g, 28 mmol) was dissolved in a mixture of CH₃OH-CH₂Cl₂ (1:1) followed by the addition of pTSA (1 g). The reaction was stirred for 24 h at room temperature, neutralized with triethylamine, concentrated and purified by a silica column (toluene/methanol, 3:1) to give 6-O-allyl-1-O-(4-methoxybenzyl)-(DL)-*myo*-inositol in (8.5 g, 90% yield). TLC (toluene/MeOH, 3:1): $R_f = 0.21$; ¹H NMR (300 MHz, CD₃OD): 3.19-3.34 (m, 3H), 3.60 (m, 2H), 3.71 (s, 3H, OMe), 4.08 (m, 1H), 4.29-4.34 (m, 2H, allyl), 4.52-4.65 (m, 2H, CH₂Ph), 5.07-5.29 (m, 2H, allyl), 5.94-6.04 (m, 1H, allyl), 6.83-6.92 (m, 2H, Ph), 7.30-7.35 (m, 2H, Ph); MS (positive ion ESMS, $M+Na^+$) calcd for $G_{17}H_{24}O_7Na$: 363.1420, found 363.1425. The above tetraol (7.5 g, 22) mmol) was dissolved in anhyd DMF (240 mL) and cooled to 0 °C, followed by addition of benzyl bromide (16 mL) and NaH (4.2 g). The mixture was stirred for 4 h at room temp, cooled, quenched with CH₃OH (3 mL), diluted with brine solution and extracted with EtOAc. The organic layer was concentrated, and the residue was purified by silica

column (hexane/EtOAC, 7:1) to obtain the tetra-benzylated product, 6-O-allyl-2,3,4,5tetra-O-benzyl-1-O-(4-methoxybenzyl)-(DL)-myo-inositol (14 g, 92%). TLC (toluene/ EtOAc, 3:1): $R_f = 0.55$; ¹H NMR (300 MHz, CDC_b): 3.24 (dd, J = 2.2 and 9.7 Hz, 1H), 3.31 (dd, J = 2.2 and 9.7, 1H), 3.39 (dd, J = 9.1 Hz, 1H), 3.80 (s, 3H, OMe), 3.91 (m, 1H), 4.24-4.41 (m, 2H), 4.52-4.65 (m, 4H), 4.77-4.90 (m, 6H), 5.15 (m, 2H), 5.85-6.10 (m, 1H), 6.84-6.87 (m, 2H), 7.22-7.42 (m, 22H, Ph). MS (positive ion ESMS, M+Na⁺) calcd for C₄₅H₄₈O₇Na 723.3298, found 723.3303. The above intermediate (9 g, 12.8 mmol) was dissolved in anhyd DMSO (200 mL) and treated with potassium tert-butoxide (14 g). The reaction mixture was kept at 70 ^oC for 2 h, after which it was poured onto icecold water, extracted with EtOAc. The organic layer was washed with brine and water, dried (Na₂SO₄) and concentrated. The residue was dissolved in a solution of 1 M HClacetone (1:9, 300 mL) and kept at 40 °C for 30 min, neutralized with triethylamine and concentrated. The residue on silica column purification (hexane/EtOAc, 4:1) afforded 2,3,4,5-tetra-O-benzyl-1-O-(4-methoxybenzyl)-(DL)-mvo-inositol (7, 7.6 g, 90%) as a colorless foam. TLC (hexane/EtOAc, 4:1): $R_f = 0.25$. ¹H NMR (300 MHz, CDC₃): 2.59 (s, 1H, OH), 3.15 (dd, J = 1.8 and 9.8 Hz, 1H, 3-H), 3.35 (dd, J = 9.8 Hz, 1H, 5-H), 3.37 (dd, J = 2.0 and 9.6 Hz, 1H, 1-H), 3.79 (s, 3H, OMe), 4.10 (bs, 1H), 4.08 (dd, J = 9.8 Hz)1H), 4.14 (m, 1H, 6H), 4.42-4.92 (m, 10H, CH₂Ph), 6.84-6.88 (m, 2H, Ph), 7.20-7.40 (m, 22H, Ph); ¹³C NMR (75 MHz, CDCk): 55.23, 71.89, 72.80, 72.86, 73.66, 74.01, 75.28, 75.73, 76.49, 76.62, 77.04, 77.46, 79.74, 81.07, 81.38, 83.46, 113.87, 127.32, 127.45, 127.50, 127.57, 127.60, 127.69, 127.81, 127.99, 128.12, 128.25, 128.33, 128.35, 129.34, 129.97, 138.81, 138.86, 159.31; MS (positive ion ESMS, M+Na⁺) calcd for $C_{42}H_{44}O_7Na$ 683.2985, found 683.2990.

$(3,4,6-Tri-O-acetyl-2-azido-2-deoxy-a -D-glucopyranosyl)-(1\rightarrow 6)-2,3,4,5-tetra-O-ben$

zyl-1-*O*-(**4-methoxybenzyl**)-(**DL**)-*myo*-inositol (15). A mixture of 2,3,4,5-tetra-*O*-benzyl -1-*O*-(4-methoxybenzyl)-(**DL**)-*myo*-inositol acceptor **7** (7.8 g, 11.5 mmol) and 3,4,6-tri-*O*-acetyl-2-azido-2-deoxy- β -D-glucopyranosyl-trichloroacetimidate (**6**, 10.5 g, 22 mmol, 1.6 equiv, prepared from tri-*O*-acetyl-D-glucal by a reported³ azidonitration method), and freshly activated powdered 4A molecular sieves were dried by azeotropic removal of residual moisture through toluene. The mixture was dissolved in anhyd CH₂Cl₂ (70 mL), stirred under argon at room temperature for 30 min, and then cooled to 0 °C. To the above suspension was added a solution of TMSOTf (2 mL, 0.2 M solution in CH₂Cl₂) drop-wise and the mixture was stirred further for 40 min at 0 °C. After completion, the reaction mixture was neutralized with triethyamine, filtered through celite and concentrated. The silica column chromatography (hexane/EtOAc, 3:1)) provided the product 15 (12 g, 90%, 1:1 diastereoisomeric mixture) as colorless solid. TLC (hexane/ EtOAc, 7:4): $R_f = 0.43$. ¹H NMR (300 MHz, CDC_k): 1.83-2.07 (3x s, 9H, OAc), 3.11-3.15 (m, 1H), 3.39-3.42 (m, 2H), 3.44-3.46 (dd, J = 9.6 Hz, 1H), 3.47-3.50 (dd, J = 1.8and 9.5 Hz, 1H), 3.60-3.63 (m, 2H), 3.82 (s, 3H, OCH₃), 4.06 (s, 1H), 4.13-4.14 (dd, J =9.5 Hz, 1H), 4.20-4.33 (m, 2H), 4.40-5.18 (m, 10H, CH₂Ph), 4.92 (m, 1H), 5.40-5.43 (m, 1H), 5.64 (d, J = 3.6 Hz, 0.5H), 5.79 (d, J = 3.6 Hz, 0.5H), 6.84-6.87 (m, 2H, Ph), 7.22-7.43 (m, 22H, Ph); ¹³C NMR (75 MHz, CDCk): 20.54, 20.58, 20.63, 55.19, 60.89, 61.17, 66.73, 67.99, 68.99, 68.99, 70.57, 71.62, 71.66, 71.84, 72.77, 72.85, 73.61, 73.97, 75.04, 75.23, 75.69, 79.69, 80.74, 81.04, 81.33, 81.96, 83.41, 83.97, 97.35, 97.16, 113.83, 127.72-129.29 (multiple peaks), 138.09-138.81 (multiple peaks), 159.37, 169.48, 169.98, 170.64; HRMS (ESMS, M+Na⁺) calcd for $C_{54}H_{59}O_{14}N_3Na$ 996.3895, found 996.3885.

(2-Azido-4,6-di-O-benzylidene-2-deoxy-a-D-glucopyranosyl)-(1→6)-2,3,4,5-tetra-O-

benzyl-1-*O*-(**4-methoxybenzyl**)-**D**-*myo*-inositol (17) and other diastereoisomer (18). The above pseudodisaccharide (15, 10.4 g, 10 mmol) dissolved in a solvent mixture of anhyd CH₂Cl₂ (24 mL) and CH₃OH (96 mL) was treated with a saturated solution (1.6 mL) of sodium methoxide in CH₃OH and the reaction mixture was stirred for 24 h at room temperature. After completion of reaction, it was neutralized with cation exchange resin (Amberlite IR 120H⁺), filtered and concentrated to give 2-azido-2-deoxy- α -D-gluco pyranosyl)-(1→6)-2,3,4,5-tetra-*O*-benzyl-1-*O*-(4-methoxybenzyl)-(DL)-*myo*-inositol (16) in quantitative yield. This intermediate (8 g, 9.4 mmol) was dissolved in anhyd CH₃CN (240 mL) followed by addition of benzaldehyde-dimethylacetal (12 mL, 6.88 mmol) and camphor-sulphonic acid (1.6 g, 6.88 mmol). The reaction mixture was stirred for 24 h at rt, neutralized with Et₃N and concentrated. The residue was diluted with HOAc, organic layer washed with saturated NaHCO₃ solution, brine and H₂O. Organic layer was dried (Na₂SO₄), concentrated and purified on a silica column (hexane-EtOAc, 85:15) provided



desired D-inositol isomer 17 (4.12 g, 47%) TLC (hexane/EtOAc, 7:3), $\mathbf{R} = 0.35$; $[\alpha]_{D} =$ +57 (c = 1.0, CHC_k); ¹H NMR (300 MHz, CDC_k): 3.10 (dd, J = 3.9 and 10 Hz, 1H), 3.38 (dd, J = 2.2 and 9.8 Hz, 1H), 3.45 (m, 4H), 3.76 (s, 3H), 3.98 (bs, 1H), 4.05-4.11 (m, 4H), 4.24 (dd, J = 9.3 Hz, 1H), 4.45 (br s, 2H), 4.60-4.94 (m, 8H), 5.35 (s, 1H), 5.72 (d, J = 3.9 Hz, 1H), 6.81-6.84 (m, 2H), 7.14-7.27 (m, 27H); ¹³C NMR (75 MHz, CDCk): 55.20, 61.92, 62.90, 68.53, 71.74, 72.73, 73.51, 74.20, 75.04, 75.35, 75.65, 80.79, 81.27, 81.84, 81.91, 97.70, 101.85, 113.81, 126.38, 127.12, 127.38, 127.58, 127.65, 127.87, 128.04, 128.14, 128.16, 128.28, 128.33, 129.04, 129.55, 129.66, 136.99, 138.16, 138.50, 138.80, 159.31; HRMS (ESMS, M+Na⁺) calcd for C₅₅H₅₇O₁₁N₃Na 958.3891, found 958.3885; and the L-inositol isomer 18 (4.2 g, 48%). TLC (hexane/EtOAc, 7:3), $R_f =$ 0.42; $[\alpha]_D = +43$ (c = 1.0, CHCb) ¹H NMR (300 MHz, CDCb): 3.17-3.18 (dd, J = 3.9 and 9.8 Hz, 1H), 3.30 (dd, J = 1.8 and 9.8 Hz, 1H), 3.35-3.39 (dd, J = 2.1 and 9.6 Hz, 1H), 3.47 (t, J = 9.3 Hz, 1H), 3.59-3.65 (dd, J = 10 Hz, 2H), 3.71 (s, 3H), 3.82 (t, J = 5 Hz, 1H), 3.94 (br s, 1H), 4.10 (dd, J = 9.6 Hz, 2H), 4.17-4.23 (m, 2H), 4.33 (t, J = 9.6 Hz, 1H), 4.40-5.02 (m, 10H), 5.51 (s, 1H), 5.59 (d, J = 3.9 Hz, 1H), 6.78-6.81 (d, 2H), 7.28-7.38 (m, 27H); ¹³C NMR (75 MHz, CDCk): 55.11, 61.65, 63.05, 68.73, 68.88, 72.10, 72.60, 74.36, 74.65, 75.01, 75.58, 77.77, 80.47, 81.78, 82.04, 84.29, 97.88, 101.88, 113.92, 126.29, 127.34, 127.38, 127.45, 127.56, 127.69, 127.81, 128.10, 128.21, 128.26, 128.29, 128.36, 129.11, 129.45, 129.75, 137.21-138.60 (multiple peaks), 159.28; HRMS $(ESMS, M+Na^{+})$ calcd for $C_{55}H_{57}O_{11}N_{3}Na$ 958.3891, found 958.3883

(2-Azido-3,6-di-*O*-benzyl-2-deoxy-a -D-glucopyranosyl)-(1 \rightarrow 6)-2,3,4,5-tetra-*O*-benyl -1-*O*-(4-methoxybenzyl)-D-*myo*-inositol (5). Compound 17 (4 g, 4.24 mmol) was dissolved in anhyd DMF (60 mL) followed by the addition of benzyl bromide (2.0 mL, 16.8 mmol) and NaH (1.2 g, 52 mmol) at 0 ^oC. After 30 min, the reaction was brought to room temperature and stirred for 4 h. After completion, the excess of NaH was destroyed by addition of a few drops of methanol. The nixture was diluted with excess of EtOAc, which was wash with saturated solution of NaHCO₃, water, dried over NaSO₄ and concentrated. Silica column chromatography (hexane/EtOAc, 9:1) afforded, 2-azido-3-*O*benzyl-4,6-*O*-benzylidene-2-deoxy- α -D-glucopyranosyl)-(1 \rightarrow 6)-2,3,4,5-tetra-*O*-benzyl-1-*O*-(4-methoxybenzyl)-D-*myo*-inositol (4.28 g, 98%), as colorless syrup. TLC

(hexane/EtOAc, 8:2) $R_f = 0.50$; $[\alpha]_D = +48$ (c = 1.0, CHCl₃). ¹H NMR (300 MHz, CDC_b): 3.24 (dd, J = 3.8 and 10.0 Hz, 1H, 2b-H), 3.38 (dd, J = 2.2 and 9.8, 1H, 1a-H or 3a-H), 3.45 (dd, J = 2.2 and 9.8, 1H, 1a-H or 3a-H), 3.46 (dd, J = 9.3 Hz, 1H), 3.52 (m, 2H), 3.80 (s, 3H, OCH₃), 3.96-4.04 (m, 2H, 2a-H, 3a-H), 4.06-4.29 (m, 4H), 4.48 (s, 2H, CH_2Ph), 4.57-4.96 (m, 10H, CH_2Ph), 5.47 (s, 1H), 5.72 (d, J = 3.8 Hz, 1H, 1b-H), 6.83-6.89 (m, 2H, Ph), 7.08-7.13 (m, 2H, Ph), 7.17-7.45 (m, 30H, Ph); ¹³C NMR (75 MHz, CDCh): 55.20, 62.83, 68.67, 71.77, 72.70, 73.50, 74.16, 74.72, 74.99, 75.49, 75.57, 77.36, 80.81, 81.13, 81.84, 82.92, 97.71, 101.14, 113.86, 126.03, 126.15, 127.60, 127.63, 127.80, 127.92, 128.13, 128.17, 128.20, 128.24, 128.31, 128.34, 129.60, 130.00, 137.48, 137.85, 137.97, 138.15, 138.59, 138.81, 159.30; HRMS (ESMS, M+Na⁺) calcd for $C_{62}H_{63}O_{11}N_3Na$ 1048.4360, found 1048.4366. To a solution of above compound (4 g, 3.88 mmol), sodium cyanoborohydride (2.7 g, 40 mmol), freshly activated moleculer sieves (4A) in anhyd THF (140 mL), at 0 °C under argon, was added drop-wise a saturated solution of HCl in diethyl-ether till pH 1 was reached. After stirring at 0 ⁰C for 30 min, the reaction mixture was neutralized with Et₃N, diluted with EtOAc and concentrated. The residue was purified on a silica column (hexane/EtOAc, 8:2) to provide desired compound 5 (3.3 g, 82%) and colorless solid. TLC (hexane/EtOAc, 5:2) $R_f =$ 0.46; $[\alpha]_{D} = +33.2$ (c = 1.4, CHCl₃). ¹H NMR (300 MHz, CDCl₃): 1.92 (d, J = 3.7, 1H, OH), 3.17 (dd, J 3.8 and 9.9 Hz, 1H, 2b-H), 3.22 (m, 1H, 6b-H), 3.28 (dd, J = 3.8 and 10.5 Hz, 1H, 6'b-H), 3.38 (dd, J = 2.2 and 9.8 Hz, 1H, 3a-H), 3.44 (m, 1H, 5a-H), 3.47 (dd, J = 2.2 and 9.8 Hz, 1H, 1a-H), 3.68 (m, 1H, 4b-H), 3.76 (m, 1H, 3b-H), 3.80 (s, 3H, 3H)OCH₃), 3.95 (m, 1H, 5b-H), 4.01 (dd, J = 2.2 Hz, 1H, 2a-H), 4.11 (dd, J = 9.4 Hz, 1H, 4a-H), 4.25 (m, 1H, 6a-H), 4.23-5.04 (m, 14H, CH₂Ph), 5.72 (d, J = 3.7 Hz, 1H, 1b-H), 6.82-6.88 (m, 2H, Ph), 7.17-7.45 (m, 32H, Ph); ¹³C NMR (75 MHz, CDCh): 55.20, 62.66, 69.00, 69.30, 71.78, 72.18, 72.64, 73.32, 73.45, 74.16, 74.21, 74.68, 74.76, 75.49, 75.60, 79.27, 80.80, 81.54, 81.84, 81.90, 84.35, 97.30, 113,78, 127.49-129.96 (multiple peaks), 137.92, 138.17, 138.33, 138.43, 138.57, 138.83, 159.28; HRMS (ESMS, M+Na⁺) calcd for $C_{62}H_{65}O_{11}N_3Na$ 1050.4517, found 1050.4521. The NMR spectral data and the optical rotation of 5 were identical to that reported⁴ for this compound prepared by another route.

 $(2-Azido-3,6-di-O-benzyl-2-deoxy-a -D-glucopyranosyl)-(1\rightarrow 6)-2,3,4,5-tetra-O-benyl - 1-O-(4-methoxybenzyl)-L-myo-inositol (19). An identical method, described above for compound 5, was used for the preparation of diastereoisomeric compound 19.$

2,3,4,6-Tetra-O-benzyl-a-D-mannopyranosyl trichloroacetimidate (11). D-Mannose (20 g, 111 mmol) was heated at 80 ^oC for 3 h in presence of BF₃.Et₂O (1 ml, 7.7 mmol) in allyl alcohol (230 mL). After neutralization with NEt₃, the excess of allyl alcohol was evaporated, and the residue purified by silica column chromatography (CH₂Ch/MeOH; 9:1 to 8:2) which afforded an α/β -mixture of allyl- α -D-mannopyranoside (α/β ratio, 20:1) (20 g, 80%) as semisolid. TLC (CH₂Cl₂/MeOH): $R_f = 0.5$. ¹H NMR (300 MHz, D_2O): 3.42-4.11 (m, 11H), 4.72 (d, J = 2.0 Hz, 1H, 1-H), 5.06-5.21 (m, 2H, all), 5.69-5.83 (m, 1H, all); MS (ESMS, M+Na⁺) calcd for C₉H₁₆O₆Na 243.0845, found 243.0850. To a solution of above compound (7.5 g, 34 mmol) and benzyl bromide (24.5 mL, 180 mmol) in anhyd DMF (160 mL) was added, in portions, NaH (7 g, 175 mmol) at 0 °C. After the mixture was stirred at 4 h, the excess of NaH was destroyed by addition of CH₃OH drop wise. The solution was diluted with EtOAc, the organic layer washed with saturated solution of NaHCO₃, brine, water, and dried (NaSO₄) and concentrated. Silica column chromatography (hexanes/EtOAc, 7:1) afforded 2,3,4,6-tetra-O-benzyl-1-O-allyl- α -D-mannopyranoside (16.4 g, 83%) as colorless foam. TLC (hexane/EtOAc, 4:1): R_f = 0.43; ¹HNMR (300 MHz, CDCk); 3.71-3.74 (m, 4H), 3.91 (m, 2H), 4.46-4.86 (m, 8H), 4.86 (d J = 1.8 Hz, 1H, H-1), 5.17-5.23 (dd, 2H, allyl), 5.80 (m, 1H), 7.19-7.28 (m, 20H); MS (ESMS, M+Na⁺) calcd for $C_{37}H_{40}O_6Na$ 603.2723, found 603.2723. For the removal of the anomeric allyl group, the above compound (16.4 g, 28 mmol) was dissolved in anyd DMSO (300 mL) and treated with potassium tert-butoxide (25 g). The reaction mixture was kept at 80 °C for 2 h, after which it was poured onto ice-cold water, extracted with EtOAc. The organic layer was washed with brine and water, dried (Na₂SO₄) and concentrated. The residue was dissolved in a solution of 1 M HCl-acetone (1:9, 300 mL) and kept at 40 °C for 30 min, neutralized with triethylamine and concentrated. The residue on silica column purification (hexane/EtOAc, 4:1) afforded 2,3,4,6-tetra-O-benzyl- α -D-mannopyranose (14 g, 95%). ¹HNMR (300 MHz, CDCk): 3.68 (dd, 5.7 and 10.8 Hz, 1H), 3.80 (bs, 1H), 3.81 (dd, J = 9.3 Hz), 1H, 3.98 (m, 3H),

4.51 (d, J = 11 Hz, 2H), 4.57 (d, J = 5.7 Hz, 2H), 4.74 (d, J = 5.7 Hz, 2H), 4.89 (d, J = 10.8 Hz), 5.29 (d, J = 1.9 Hz, 1H), 7.19-7.28 (m, 20H); ¹³C NMR (75 MHz, CDCl₃): 69.55, 72.13, 72.65, 73.29, 74.80, 74.94, 75.12, 79.62, 83.00, 93.60, 127.48-128.42 (multiple peaks), 138.32-132.40 (4 signals); MS (ESMS, M+Na⁺) calcd for $C_{34}H_{36}O_6Na$ 563.2410, found 563.2415. The above compound (5.0 g, 9.25 mmol) and CCl₃CN (5.1 mL, 35 mmol) were dissolved in anhyd CH₂Cl₂ (18 mL). After addition of DBU (300 µL) and stirring at rt for 1 h, the solvent was removed and the residue was purified by silica column (hexane/EtOAc, 8:2) affording desired donor **11** (6.1 g, 98%) as a brown viscous compound. TLC (hexane/EtOAc, 4:1): $R_f = 0.65$; ¹HNMR (300 MHz, CDCl₃): 3.75 (m, 1H), 3.88 (m, 2H), 3.99 (m, 2H), 4.16 (dd, J = 7.8 Hz, 1H), 4.55-4.88 (m, 8H), 6.37 (s, 1H), 7.19-7.41 (m, 20H), 8.53 (s, 1H, NH); MS (ESMS, M+Na⁺) calcd for $C_{36}H_{36}O_6NCl_3Na$ 706.1506, found 706.1510.

Allyl-3-O-benzyl-4,6-O-benzylidene-a-D-mannopyranoside (12). A solution of allylα-D-mannopyranoside (15 g, 68 mmol), benzaldehyde-dimethylacetal (13 mL, 76 mmol) and camphor sulphonic acid (3.0 g, 13 mmol) in anhyd CH₃CN (300 ml) was stirred at rt for 18 h. After neutralization with NEt_3 and the reaction mixture was concentrated, diluted with EtOAc and organic layer washed with saturated solution of NaHCO₃, brine and water. The organic layer dried (Na₂SO₄), concentrated and the residue was purified by silica column chromatography (hexane/EtOAc, 6:4) to provide compound allyl-4,6-Obenzylidene- α -D-mannopyranoside (15.6 g, 74%) as a colorless crystalline solid. TLC (hexane/EtOAc, 1:1): $R_f = 0.38$; ¹HNMR (300 MHz, CDCh): 3.78-3.90 (m, 2H, H-5 and H-6), 3.98 (m, 1H, H-3), 3.99 (m, 1H), 4.05-4.14 (m, 2H, H-2 and H-6), 4.19 (m, 1H), 4.24-4.28 (m, 1H, H-4), 4.92 (d, J = 1.3 Hz, 1H, H-1), 5.19-5.33 (m, 2H, allyl), 5.50 (s, 1H), 5.90 (m, 1H, allyl), 7.27-7.45 (m, 5H); ¹³C NMR (75 MHz, CDCb): 63.19, 68.01, 68.16, 68.52, 68.68, 78.79, 99.49, 102.13, 117.63, 126.22, 128.23, 129.1, 133.43, 137.17; MS (ESMS, M+Na⁺) calcd for $C_{16}H_{20}O_6Na$ 331.1158, found 331.1165. To a solution of above compound (7.8 g, 25 mmol) in anhyd DMF (100 mL) was added benzyl bromide (3 mL, 22.5 mmol) and NaH (1.3 g, 32.5 mmol) at 0 °C. The reaction mixture was stirred at rt for 4 h, excess of NaH destroyed by addition of CH₃OH, and diluted with EtOAc. The mixture was washed with saturated solution of NaHCO₃, brine and water, dried (NaSO₄) and concentrated. Silica column chromatography (hexane/EtOAc, 7:1) afforded pure compound allyl-3-*O*-benzyl-4,6-*O*-benzylidene-α-D-mannopyranoside (6.6 g, 65%) as colorless syrup. TLC (hexane/EtOAc, 7:3): $R_f = 0.40$; ¹HNMR (300 MHz, CDC_b): 3.78-3.80 (m, 2H, H5 and H-6), 3.98 (m, 1H, H3), 4.02-4.14 (m, 2H, H2 and H-6), 4.24-4.28 (m, 1H, H4), 4.78 (m, 2H, *CH*₂Ph), 4.84 (d, J = 1.3 Hz, 1H, H-1), 5.19-5.33 (m, 2H, allyl), 5.52 (s, 1H), 5.90 (ddt, 1H, allyl), 7.27-7.45 (m, 10H); ¹³C NMR (75 MHz, CDC_b): 63.53, 68.03, 68.69, 73.59, 73.63, 73.70, 78.52, 79.46, 97.48, 101.37, 117.54, 125.99, 126.22, 127.89, 127.98, 128.17, 128.32, 128.38, 128.49, 128.99, 133.37, 137.31; MS (ESMS, M+Na⁺) calcd for C₂₃H₂₆O₆Na 421.1627, found 421.1633.

3,4,6,-Tri-O-benzyl-b-D-mannopyranose-1,2-pen-4-enylorthobenzoate (13). The penta-O-benzoyl-D-mannose (30 g, 42 mmol) was dissolved in CH₂Cl₂ (150 mL) and cooled to 0 °C and treated with a solution of 30% HBr-AcOH (100 mL). The reaction mixture was stirred at rt for 12 h, diluted with CH₂Cl₂ (250 mL) and cold saturated NaHCO₃ solution (150 mL) and stirred for 30 min. The organic layer was washed with brine, dried (Na₂SO₄), concentrated, and puried by silica column (hexane/EtOAc, 4:1) to get the mannosyl bromide (23 g), TLC (hexane/EtOAc, 4:1): $R_f = 0.50$, all of which (23 g, 48 mmol) was dissolved in CH2Ch2 (100 mL) and treated with 2,6-lutidine (14 mL, 142 mmol) and 4-penten-1-ol (7.05 ml, 68.5 mmol). After five days of stirring at rt, the reaction mixture was diluted with CH₂Cl₂, washed with saturated aqueous NaHCO₃ and brine, dried over Na₂SO₄ and concentrated. Silica chromatography (hexane/EtOAc, 3:1) afforded 3,4,6,-tri-O-benzoyl- β -D-mannopyranose-1,2-pen-4-enylorthobenzoate (23 g) as colorless solid. TLC (hexane/EtOAc, 4:1): $R_f = 0.30$; ¹H and ¹³C NMR data of this intermediate was identical to the previously reported.⁵ The compound (9.0 g, 14. mmol) dissolved in CH₂Ch₂:CH₃OH (72 mL, 8:1) was treated with sodium methoxide (400 mg, 7.4 mmol) and the reaction mixture stirred at room temperature for 2 h. After removal of solvent and column chromatography $(CH_3OH:CH_2Cl_2,$ 95:5) provided fully debenzoylated derivative (4.2 g, 86%) colorless foam which (4.2 g, 12 mmol) was dissolved in anhyd DMF (50 mL) and benzyl bromide (7.4 ml, 54.36 mmol) and NaH (2.9 g, 72.5 mmol) were added at 0 $^{\circ}$ C. After 1 h, the reaction was brought to rt and stirred for overnight. After completion of the reaction, the excess of NaH was destroyed

by addition methanol (5 mL) and concentrated. The residue was diluted with EtOAc, washed with saturated solution of NaHCO₃, brine and water respectively, dried over NaSO₄ and concentrated. Flash chromatography (hexane/EtOAc, 4:1) afforded compound **13** (7.0 g, 93%) as colorless syrup. TLC (hexane/EtOAc, 4:1): $R_f = 0.42$; ¹H NMR (300 MHz, CDCl₃): 1.71-1.82 (m, 2H), 2.18-2.26 (m, 2H), 3.40-3.69 (m, 4H), 3.80-3.94 (m, 2H), 4.85-5.13 (m, 6H), 5.52 (d, J = 3 Hz, 1H), 5.87 (m, 1H), 7.78-7.20 (m, 20H); ¹³C NMR (75 MHz, CDCl₃): 28.77, 30.19, 63.30, 69.09, 72.08, 73.14, 74.33, 74.95, 75.02, 76.13, 78.43, 97.72, 114.80, 122.10, 126.61, 127.27, 127.37, 127.86, 127.87, 127.95, 128.13, 128.27, 128.40, 137.84, 137.95; MS (ESMS, M+Na⁺) calcd for C₃₉H₄₂O₇Na 645.2828, found 645.2835.

Allyl-2,3,4-tri-*O*-benzyl-**a**-D-mannopyranoside (14). $1-O-Allyl-\alpha-D-mannopyranose$ (24 g, 109 mmol) dissolved in anhyd pyridine (100 mL) was treated with trityl chloride (26 g, 93 mmol) and the reaction mixture was stirred over night at 80 °C. The excess of pyridine was removed by distillation at reduced pressure and residue diluted with EtOAc, washed with saturated solution of NaHCO₃, brine and water, dried over Na₂SO₄ and concentrated. Silica column chromatography (CH2Cl2/MeOH, 95:5) afforded allyl-6-Otrityl- α -D-mannopyranoside (35 g, 70%) as pale yellow syrup which was dissolved in anhyd DMF (400 mL) followed by the addition of benzyl bromide (58 mL) and NaH (21 g) at 0 °C. After 30 min, the reaction was brought to rt and stirred for 4 h. After completion, the excess of NaH was destroyed by addition of methanol and concentrated. The mixture was diluted with EtOAc, which was wash with saturated solution of NaHCO₃, water, dried over NaSO₄ and concentrated. Silica column chromatography (hexane/EtOAc, 3:1) afforded allyl-2,3,4-tri-O-benzyl-6-O-trityl- α -D-mannopyranoside (49 g, 89%). The above compound (49 g, 67 mmol) dissolved in a solvent mixture of CH₂Cl₂-CH₃OH (720 mL, 1:3) was treated with p-toulene-sulponic acid (3.6 g) and stirred for 12 h at rt. After completion of the reaction, the reaction was neutralized with Et₃N and concentrated. Silica column chromatography (hexane/EtOAc, 7:3) afforded allyl-2,3,4-tri-O-benzyl- α -D-mannopyranoside (30 g, 93%) as colorless foam. TLC (hexane/EtOAc, 7:3), $R_f = 0.25$; ¹HNMR (300 MHz, CDCk): 3.61 (m, 1H), 3.76 (m, 1H),

1.3 Hz, 1H), 5.19-5.33 (m, 2H), 5.78 (m, 1H), 7.24-7.31 (m, 15H); 13 C NMR (75 MHz, CDCl₃): 61.86, 67.65, 72.01, 72.61, 72.78, 74.76, 74.95, 80.10, 97.24, 117.00, 127.43, 127.49, 127.55, 127.73, 127.86, 128.14, 128.23, 133.74, 138.26, 138.48, 138.53; MS (ESMS, M+Na⁺) calcd for C₃₀H₃₄O₆Na 513.2253, found 513.2260.

2,3,4,6-Tetra-*O*-benzyl-**a**-D-mannopyranosyl-(1 ® 2)-3-*O*-benzyl-4,5-di-*O*-acetyl-**a**-D-mannopyranosyl trichloroacetimidate (9).

(a) Allyl (2,3,4,6-tetra-O-benzyl)-**a**-D-mannopyranosyl-(1 ® 2)-3-O-benzyl-4,6-O-benzyli dene-a-D-mannopyranoside. The glycosyl donar (11, 2,3,4,6-tetra-O-benzyl- α -D-manno pyranosyl trichloroacetimidate, 4.1 g, 6.0 mmol) and the acceptor (12, allyl-3-O-benzyl-4,6-O-benzylidene- α -D-mannopyranoside, 1.75 g, 4.39 mmol) were dried through anhyd toluene and then dissolved in anhyd diethyl-ether (100 mL) under argon. After addition of TMSOTf solution (2.95 mL, 0.1 N in anhyd diethyl-ether), the reaction mixture was stirred for 2 h at rt. This was followed by neutralization with Et₃N, concentration and silica column chromatography (hexane/EtOAc, 7:1) to obtain desired compound (4.4 g, 81%) as a colorless crystalline solid. TLC (hexane/EtOAc, 3:1): $R_f = 0.36$; ¹HNMR (300) MHz, CDCk): 3.70 (m, 2H), 3.75-4.00 (m, 6H), 4.10-4.25 (m, 3H), 4.30 (m, 1H), 4.40 (t, 1H), 4.45-5.00 (m, 11H), 5.15-5.30 (m, 2H), 5.41 (s, 1H), 5.58 (s, 1H), 5.80 (m, 1H), 7.09-7.50 (m, 30H); ¹³C NMR (75 MHz, CDCh): 64.05, 67.94, 68.03, 68.69, 68.79, 69.32, 71.60, 72.41, 73.23, 73.34, 73.42, 73.69, 74.07, 74.77, 74.81, 77.55, 78.51, 79.23, 79.50, 98.23, 98.69, 102.03, 117.47, 126.13, 127.20, 127.27, 127.33, 127.48, 127.52, 127.64, 127.68, 127.74, 127.87, 128.00, 128.12, 128.16, 128.19, 128.22, 128.27, 128.32, 128.39, 128.49, 129.12, 133.37, 137.54, 137.75, 138.11, 138.38, 138.41, 138.72; HRMS $(ESMS, M+Na^{+})$ calcd for $C_{57}H_{60}O_{11}Na$ 943.4033, found 943.4040.

(b) 2,3,4,6-tetra-O-benzyl-**a**-D-mannopyranosyl-($1 \otimes 2$)-3-O-benzyl-**a**-D-mannopyranosi de. The above mannobiose intermediate (2.0 g, 2.19 mmol) dissolved in DMSO (90 mL) was treated with potassium *t*-butaoxide (7 g, 62.5 mmol) and the reaction mixture was stirred at 80^{°0}C for 3 h. After completion of the reaction, ice was added and the mixture extracted with EtOAc. The organic layer was dried with Na₂SO₄ and concentrated to provide thick syrup. This was dissolved in a mixture of acetone:1M HCl (9:1, 79 mL) and heated at $55^{\circ0}$ C for 2 h, the progress of reaction checked by TLC. The reaction mixture was cooled, neutralized with NEt₃ and concentrated. Flash chromatography (hexane/EtOAc, 1:1) provided desired compound (1.4 g, 82%) as colorless foam. TLC (hexane/EtOAc, 3:7): $R_f = 0.34$; ¹HNMR (300 MHz, CDC_b): 3.58 (m, 2H), 3.75 (m, 5H), 3.85 (m, 3H), 4.00 (bs, 2H), 4.43-4.54 (m, 10H), 5.06 (bs, 1H), 5.34 (d, J = 1.9 Hz, 1H), 7.12-7.24 (m, 25H); ¹³C NMR (75 MHz, CDC_b): 62.38, 62.84, 67.34, 67.70, 69.57, 69.73, 71.56, 72.12, 72.32, 72.43, 72.58, 72.67, 73.31, 74.53, 74.87, 75.12, 77.32, 77.65, 79.27, 92.37, 98.70, 127.44-128.31 (multiple peaks), 137.93-138.08 (5 peaks); HRMS (positive ion ESMS, M+Na⁺) calcd for C₄₇H₅₂O₁₁Na 815.3407, found 815.3412.

(c) Acetyl-(2,3,4,6-tetra-O-benzyl-a-D-mannopyranosyl)-(1 @2)-3-O-benzyl-4,5-di-Oacetyl-a-D-mannopyranoside. A solution of preceding deprotected intermediate (1.4 g, 1.78 mmol) in a mixture of pyridine and acetic anhydride (1:1, 6 equivalent) was stirred at 0° C for 15 min and then kept at rt overnight. This was followed by addition of ice and stirring for 30 min, extraction with EtOAc. The organic layer was washed with saturated solution of $NaHCO_3$ and water, dried with Na_2SO_4 and concentrated. Flash chromatography (hexane/EtOAc, 3:1) afforded desired triacetylated compound (1.45 g, 93.35%) as colorless syrup. TLC (hexane/EtOac, 7:3) $R_f = 0.58$; ¹HNMR (300 MHz, CDC_{h}): 1.84 (s, 3H), 1.96 (s, 3H), 2,03 (s, 3H), 3.75 (m, 1H), 4.10 (dd, J = 3 and 12 Hz, 1H), 4.15 (dd, J = 5Hz, 1H), 4.35 (m, 3H), 4.50-4.60 (m, 6H), 4.70 (t, J = 11 Hz, 1H), 4.96 (d, J = 2 Hz, 1H), 5.23 (s, 1H), 5.30 (t, J = 10 Hz, 1H), 6.13 (d J = 2 Hz, 1H), 7.25-7.53 (m, 25H); ¹³C NMR (75 MHz, CDCb): 20.54, 20.64, 20.71, 61.50, 62.47, 67.71, 69.63, 71.08, 71.93, 72.31, 72.40, 72.46, 72.69, 73.24, 74.01, 74.34, 75.04, 75.49, 75.80, 77.10, 79.49, 90.89, 100.60, 127.40-128.32 (multiple peaks), 138.12-138.38 (5 peaks), 167.99, 168.54, 170.70; HRMS (positive ion ESMS, M+Na⁺) calcd for C₅₃H₅₈O₁₄Na 941.3724, found 941.3730.

(d) 2,3,4,6-*Tetra-O-benzyl-a-D-mannopyranosyl-(1* $\otimes 2$)-3-O-benzyl-4,5-di-O-acetyl-a-D-mannopyranoside. A solution of previous acetylated compound (1.0 g, 1.14 mmol) in a saturated solution of dimethylamine in CH₃CN (55 mL) was stirred at -20° C for 1 h. the excess of solvent and reagent was carefully removed by evaporation under reduced pressure without heating. Flash chromatography (hexane/EtOAc, 3:1) provided compound **9** (0.9 g, 94%) as colorless foam. TLC (hexane/EtOAc, 7:3), $R_f = 0.34$; ¹HNMR (300 MHz, CDCl₃): 3.75 (m, 2H), 3.90 (m, 1H), 3.90-4.25 (m, 7H), 4.25-4.56 (m, 10H), 4.75 (t, 1H), 4.90 (d, J = 1.9 Hz, 1H), 5.08 (d, J = 1.9 Hz, 1H), 5.27 (t, 1H), 7.10-7.26 (m, 25H); ¹³C NMR (75 MHz, CDCl₃): 20.67, 20.71, 62.67, 62.90, 68.38, 68.71, 69.65, 72.18, 72.27, 72.55, 72.60, 72.67, 72.92, 72.97, 73.27, 74.35, 74.44, 74.03, 75.22, 77.21, 79.66, 92.45, 100.33, 127.37-128.29 (multiple peaks), 138.02-138.30 (5 peaks), 169.47, 170.77; HRMS (positive ion ESMS, M+Na⁺) calcd for C₅₁H₅₆O₁₃Na 899.3619, found 899.3625.

(e) 2,3,4,6-Tetra-O-benzyl-**a**-D-mannopyranosyl-(1 \circledast 2)-3-O-benzyl-4,5-di-O-acetyl-**a**-D-mannopyranosyl trichloroacetimidate (**9**). To a solution of compound **9** (800 mg, 0.69 mmol) in anhyd CH₂Ch₂ (10 mL) was added Ch₃CCN (1.7 ml, 17 mmol) and DBU (90 μ L) and the reaction mixture was stirred at rt for 1 h. The solvent was removed and the residue was purified by a silica column chromatography (hexane/EtOAc, 3:1) to afford compound **10** (890 mg, 96%) as colorless foam. TLC (hexane/EtOAc, 7:3): R_f = 0.50; ¹HNMR (300 MHz, CDCh₃): 3.76 (m, 2H), 3.93 (m, 1H), 3.95-4.25 (m, 7H), 4.26-4.56 (m, 10H), 4.75 (t, 1H), 5.08 (d, J = 1.9 Hz, 1H), 5.27 (t, 1H), 6.30 (bs, 1H), 7.10-7.26 (m, 25H), 8.60 (s, 1H, NH); HRMS (ESMS, M+Na⁺) calcd for C₅₃H₅₆O₁₃NCl₃Na 1042.2715, found 1042.2720.

Allyl (3,4,6-tri-*O*-benzyl-a -D-mannopyranosyl)-(1 \rightarrow 6)-2,3,4-tri-*O*-benzyl-a -D-mann opyranose (10). The orthoester donor 13 (1.85 g, 3.11 mmol) and mannobiose acceptor 14 (1.55 g, 3.16 mmol) were dissolved in anhyd CH₂Ch₂ (15 mL) and freshly activated 4A° molecular sieves were added. The solution was stirred at rt for 30 min followed by addition of 0.1 N solution of TESOTf in CH₂Ch₂ (150 µL, 15 mmol) and Niodosuccinimide (525 mg, 2.34 mmol). After 30 min stirring, the solution was neutralized with Et₃N, the solvent was evaporated and the residue purified by column chromatography (hexane/EtOAc, 85:15), which provided allyl (2-*O*-benzoyl-3,4,6-tri-*O*benzyl- α -D-mannopyranosyl)-(1 \rightarrow 6)-2,3,4-tri-*O*-benzyl- α -D-mannopyranose (2.31 g,

72%) as colorless syrup. TLC (hexane/EtOAc, 7:3) $R_f = 0.5$; ¹HNMR (300 MHz, CDCk): 3.50-4.00 (m, 7H), 4.12-4.25 (m, 4H), 4.50-5.10 (m, 11H), 5.19 (d, J = 1.9 Hz, 1H), 5.20 (t, 1H), 5.90 (m, 1H), 7.24-8.10 (m, 35H); ¹³C NMR (75 MHz, CDCh): 66.68, 67.78, 68.74, 69.00, 71.09, 71.65, 72.06, 72.70, 73.35, 74.23, 74.65, 74.76, 75.03, 75.11, 77.67, 80.30, 96.83, 98.07, 117.45, 127.51-128.35 (multiple peaks), 133.68, 138.49 (multiple peaks), 165.49; HRMS (positive ion ESMS, $M+Na^+$) calcd for $C_{64}H_{66}O_{12}Na$ 1049.4452, found 1049.4463. To a solution of above compound (2.3 g, 2.24 mmol) in a solvent mixture of CH₃OH-CH₂Cl₂ (20 mL, 7:1) was added sodium methoxide (350 mg, 6.48 mmol). The solution was stirred at rt for 3 h. After completion of the reaction, the solvent was evaporated and the residue was purified by silica column chromatography (hexane/EtOAc, 3:1) to get compound 10 (1.9 g, 92%) as colorless foam. TLC (hexane/EtOAc, 7:3) $R_f = 0.25$; ¹HNMR (300 MHz, CDCk): 3.50-3.60 (m, 2H), 3.62-3.70 (m, 2H), 3.75-3.80 (m, 4H), 4.0 (m, 4H), 4.35-4.75 (m, 12H), 5.0 (bs, 1H), 5.10-5.15 (m, 2H), 5.80 (m, 1H), 7.18-7.29 (m, 30H); ¹³C NMR (75 MHz, CDCk): 66.24, 67.76, 68.04, 68.87, 71.06, 71.44, 71.62, 72.08, 72.73, 73.32, 74.23, 74.63, 74.89, 75.01, 79.56, 80.20, 96.84, 99.59, 117.39, 127.62-128.29 (multiple peaks), 133.65, 138.46-138.50 (multiple peaks); HRMS (positive ion ESMS, $M+Na^+$) calcd for $C_{57}H_{62}O_{11}Na$ 945.4190, found 945.4197.

(2,3,4,6-Tetra-O-benzyl-**a**-D-mannopyranosyl)- $(1\rightarrow 2)$ -(4,6-di-O-acetyl-3-O-benzyl-**a**-D-mannopyranosyl)- $(1\rightarrow 2)$ -(3,4,6-tri-O-benzyl-**a**-D-mannopyranosyl)- $(1\rightarrow 6)$ -(2,3,4-tri-O-benzyl-**a**-D-mannopyranosyl)-trichloroacetimidate (8).

(a) Allyl (2,3,4,6-tetra-O-benzyl-**a**-D-mannopyranosyl)- $(1\rightarrow 2)$ -(4,6-di-O-acetyl-3-Obenzyl-**a**-D-mannopyranosyl)- $(1\rightarrow 2)$ -(3,4,6-tri-O-benzyl-**a**-D-mannopyranosyl)- $(1\rightarrow 6)$ -2,3,4-tri-O-benzyl-**a**-D-mannopyranose. The mannobiosyl donor (2,3,4,6-tetra-O-benzyl- α -D-mannopyranosyl- $(1\rightarrow 2)$ -3-O-benzyl-4,5-di-O-acetyl- α -D-mannopyranosyl trichloro acetimidate, **9**, 1.0 g, 1.08 mmol) and the acceptor (allyl (3,4,6-tri-O-benzyl- α -Dmannopyranosyl)- $(1\rightarrow 6)$ -2,3,4-tri-O-benzyl- α -D-mannopyranose, **10**, 650 mg, 0.63 mmol) were first dried through co-evaporation with anhyd toluene, further dried for 2 h under high vacuum, and then dissolved in anhyd CH₂Cl₂ (12 mL) and freshly activated molecular sieves (4 A°) were added and the suspension stirred under argon at rt for 30 min. The reaction mixture was cooled to 0 0 C and treated with 0.1 N TMSOTf solution (760 µL, 0.76 mmol) and stirred for 30 min. The reaction was neutralized with Et₃N and solvent was evaporated. The residue was purified by column chromatography (hexane/EtOAc, 85:15) to provide target tetrasaccharide (1.05 g, 69%). TLC (hexane/EtOAc, 7:3) R_f = 0.68. This glycosylation reaction required strictly anhydrous conditions; ¹H NMR (300 MHz, CDCl₃); 1.80 (s, 3H), 2.01 (s, 3H), 3.52-4.32 (m, 22H), 4.35-500 (m, 26H), 5.05-5.40 (m, 5H), 5.29 (t, 1H), 5.77-5.87 (m, 1H), 7.16-7.29 (m, 55H); ¹³C NMR (75 MHz, CDCl₃): 20.57, 20.64, 62.87, 66.53, 67.69, 68.47, 68.86, 69.01, 69.13, 71.34, 71.41, 71.74, 72.01, 72.20, 72.24, 72.44, 72.59, 72.99, 73.18, 74.48, 74.61, 74.70, 74.88, 75.37, 75.76, 77.13, 79.03, 79.89, 80.27, 96.87, 99.05, 99.51, 99.81, 117.34, 127.30-128.24 (multiple peaks), 133.57, 137.98-138.76 (multiple peaks), 169.44, 170.69; HRMS (positive ion ESMS, M+Na⁺) calcd for C₁₀₈H₁₁₆O₂₃Na 1803.7805, found 1803.7811.

(b) 2,3,4,6-tetra-O-benzyl-**a**-D-mannopyranosyl- $(1 \otimes 2)$ -4,6-di-O-acetyl-3-O-benzyl-**a**-D-mannopyranosyl- $(1 \otimes 2)$ -(3,4,6-tri-O-benzyl-**a**-D-mannopyranosyl)- $(1 \otimes 6)$ -2,3,4-tri-O-

benzyl-a-D-mannopyranose. To a solution of protected above tetrasaccharide (425 mg, 0.238 mmol) in AcOH-H₂O (11 ml, 19:1) was added PdC₂ (400 mg, 2.25 mmol) and anhyd NaOAc (400 mg, 4.87 mmol). The reaction mixture was stirred at rt for 16 h under argon atmoshphere. After completion of the reaction, it was diluted with EtOAc, organic layer washed with saturated NaHCO₃ solution and water, dried (Na₂SO₄) and evaporated. The residue was purified by silica chromatography (hexane/EtOAc, 7:3) to provide anomeric-deprotected tetrasaccharide (380 mg, 91%) as colorless foam. TLC (hexane/EtOAc, 6:4) $R_f = 0.3$; ¹HNMR (300 MHz, CDC₃) 1.79 (s, 3H), 2.00 (s, 3H), 3.30-4.25 (m, 22H), 4.30-4.90 (m, 24H), 4.96 (d, 1H), 5.05 (d, 1H), 5.09 (d, 1H), 5.16 (d, 1H), 5.28 (t, 1H), 7.08-7.29 (m, 55H); ¹³C NMR (75 MHz, CDC₃): 20.62, 20.76, 62.99, 68.12, 68.65, 68.87, 69.04, 69.17, 69.50, 71.34, 71.50, 71.55, 71.71, 72.01, 72.24, 72.37, 72.46, 72.62, 73.11, 73.20, 73.37, 74.02, 74.26, 74.52, 74.64, 74.78, 74.82, 74.90, 75.00, 75.09, 75.86, 75.99, 77.13, 78.59, 78.98, 79.86, 92.46, 99.09, 99.28, 99.89, 127.53-

128.27 (multiple peaks), 138.24-138.41 (multiple peaks), 169.51, 170.96; HRMS (positive ion ESMS, $M+Na^+$) calcd for $C_{105}H_{112}O_{23}Na$ 1763.7492, found 1763.7503.

(c) 2,3,4,6-Tetra-O-benzyl-**a**-D-mannopyranosyl)- $(1\rightarrow 2)$ -(4,6-di-O-acetyl-3-O-benzyl -**a**-D-mannopyranosyl)- $(1\rightarrow 2)$ -(3,4,6-tri-O-benzyl-**a**-D-mannopyranosyl)- $(1\rightarrow 6)$ -(2,3,4-tri-O-benzyl-**a**-D-mannopyranosyl)- $(1\rightarrow 6)$ -(2,3,4)-(2,3,4)-(3,0)-(3

mg, 0.172 mmol) was dissolved in anhyd CH₂Cl₂ (5 mL) followed by addition of CCl₃CN (0.51 mL, 5.1 mmol) and DBU (150 μ L) and the reaction was stirred at rt for 1.5 h. After completion of the reaction, the solvent was removed under reduced pressure and the residue was purified on a silica column (hexane/EtOAc, 3:1) to give desired tetrasaccharide trichloroacetimidate donor (**21**, 320 mg, 98%) as colorless foam. TLC (hexane/EtOAc, 3:1): R_f=0.53; ¹HNMR (300 MHz, CDCl₃): 1.79 (s, 3H), 2.00 (s, 3H), 3.30-4.25 (m, 22H), 4.30-4.90 (m, 24H), 5.06 (d, 2H), 5.16 (d, 1H), 5.28 (t, 1H), 6.32 (bs, 1H), 7.08-7.29 (m, 55H), 8.61 (s, 1H, NH); MS (ESMS, M-C₂NCl₃+H⁺) calcd for C₁₀₅H₁₁₂O₂₃ 1740.7594, found 1740.7599.

2,3,4,6-Tetra-*O*-benzyl-a -D-mannopyranosyl)- $(1\rightarrow 2)$ -(4,6-di-O-acetyl-3-*O*-benzyl-a -D-mannopyranosyl)- $(1\rightarrow 2)$ -(3,4,6-tri-*O*-benzyl-a -D-mannopyranosyl)- $(1\rightarrow 6)$ -(2,3,4tri-*O*-benzyl-a -D-mannopyranosyl)- $(1\rightarrow 4)$ -(2-azido-3,6-di-*O*-benzyl-2-deoxy-a -D-glu copyranosyl)- $(1\rightarrow 6)$ -2,3,4,5-tetra-*O*-benzyl-1-*O*-(4-methoxybenzyl)-D-myo-inositol (3a). The above tetramannose-trichoroacetimidate donor (2,3,4,6-tetra-*O*-benzyl- α -D-ma nnopyranosyl)- $(1\rightarrow 2)$ -(4,6-di-*O*-acetyl-3-*O*-benzyl- α -D-mannopyranosyl)- $(1\rightarrow 2)$ -(3,4,6tri-*O*-benzyl- α -D-mannopyranosyl)- $(1\rightarrow 6)$ -(2,3,4-tri-O-benzyl- α -D-mannopyranosyl)trichloroacetimidate, 8, 250 mg, 0.114 mmol) and the glucosamine-inositol acceptor (2azido-3,6-di-*O*-benzyl-2-deoxy- α -D-glucopyranosyl)- $(1\rightarrow 6)$ -2,3,4,5-tetra-*O*-benzyl-1-O-(4-methoxybenzyl)-D-*myo*-inositol, 5, 150 mg, 0.15 mmol) were dried by evaporation through anhyd toluene and then dissolved in anhyd diethyl-ether (10 mL) under argon and cooled to 0 ^oC. To this was added a solution of 0.1 N TMSOTf (320 μ L, 0.36 mmol) and reaction mixture was stirred for 30 min. After completion of reaction the reaction was neutralized with Et₃N and solvent evaporated, and residue purified by a silica column (hexane/EtOAc, 8:2) to provide desired pseudohexasaccharide **3a** (220 mg, 60%) as viscous substance. TLC (hexane/EtOAc, 3:1) $R_f = 0.25$; ¹HNMR (300 MHz, CDCl₃): 1.80 (s, 3H), 1.93 (s, 3H), 3.25-4.01 (m, 38H), 3.83 (s, 3H), 4.33-5.08 (m, 34H), 5.26 (bs, 1H), 5.28 (bs, 1H), 5.37 (bs, 1H), 5.38 (bs, 1H), 5.80 (d, J = 3.8 Hz, 1H), 6.89 (d, 2H), 7.07-7.39 (m, 87H); ¹³C NMR (75 MHz, CDCl₃): 20.61, 22.59, 55.20, 62.03, 62.77, 62.97, 65.73, 66.51, 68.09, 68.51, 68.63, 68.86, 69.01, 69.18, 69.62, 69.69, 71.48, 71.71, 71.96, 72.05, 72.10, 72.21, 72.47, 72.66, 73.01, 73.12, 73.19, 74.16, 74.50, 74.61, 74.78, 74.94, 75.07, 76.20, 77.17, 79.03, 79.94, 80.04, 80.85, 81.52, 81.82, 81.87, 97.28, 99.23, 99.35, 99.80, 100.29, 113.92, 127.19-128.23 (multiple peaks), 129.44, 138.04-138.85 (multiple peaks), 159.31, 169.41, 170.67; HRMS (positive ion ESMS, M+Na⁺) calcd for C₁₆₇H₁₇₅O₃₃N₃Na 2773.2006, found 2773.2010.

$(2,3,4,6-\text{Tetra}-O-\text{benzyl-}\mathbf{a}-D-\text{mannopyranosyl})-(1\rightarrow 2)-(3-O-\text{benzyl-}6-O-\text{tert-butyldi})$ phenylsilyl- \mathbf{a} -D-mannopyranosyl)-(1\rightarrow 2)-(3,4,6-\text{tri-}O-\text{benzyl-}\mathbf{a}-D-\text{mannopyranosyl})-(1\rightarrow 6)-(2,3,4-\text{tri-}O-\text{benzyl-}\mathbf{a}-D-\text{mannopyranosyl})-(1\rightarrow 4)-(2-\text{azido}-3,6-\text{di-}O-\text{benzyl-}2-\text{constraints})-(1\rightarrow 4)-(2-\text{azido}-3,6-\text{di-}O-\text{constraints})-(1\rightarrow 4)-(2-\text{azido}-3,6-\text{di-}O-\text{constraints})-(1\rightarrow 4)-(2-\text{azido}-3,6-\text{di-}O-\text{constraints})-(1\rightarrow 4)-(2-\text{azido}-3,6-\text{di-}O-\text{constraints})-(1\rightarrow 4)-(2-\text{azido}-3,6-\text{di-}O-\text{constraints})-(1\rightarrow 4)-(2-\text{azido}-3

deoxy-**a**-D-glucopyranosyl)-(1 \rightarrow 6)-2,3,4,5-tetra-O-benzyl-1-O-(4-methoxybenzyl)-D**myo-inositol** (3c). The above pseudohexasaccharide 3a (85 mg, 0.03 mmol) was dissolved in a solvent mixture of CH₃OH-CH₂Cl₂ (3:1, 6 mL) followed by addition of sodium methoxide (90 mg, 1.66 mmol). The reaction was stirred at rt for 1h, solvent was evaporated under reduced pressure and the residue purified by a silica column (hexane/EtOAc, 65:35) to obtain desired deacetylated pseudohexasaccharide 3b (80 mg, 97%) as colorless solid which was dissolved in anhyd THF (1 mL) followed by addition of imidazole (25 mg, 0.36 mmol) and tert-butyldiphenylsilyl chloride (TBDPSCl, 60 µL, 0.23 mmol). The reaction mixture was stirred for 5 h, diluted with EtOAc, organic layer washed with saturated aq solution of NaHCO3 and H2O, dried over Na2SO4 and concentrated. The residue was purified through a small silica column to provide selectively silvlated compound 3c (82 mg, 94%). TLC (hexane/EtOAc, 7:3) $R_f = 0.40$; ¹HNMR (300 MHz, CDCk): 1.15 (s, 9H, TBDPS), 3.07-4.05 (m, 36H), 3.73 (s, 3H), 4.10-4.95 (m, 36H), 4.97 (bs, 1H), 5.17 (bs, 1H), 5.29 (bs, 1H), 5.42 (bs, 1H), 5.72 (d, J = 3.6 Hz, 1H), 6.80-6.82 (d, 2H), 7.04-7.26 (m, 93H), 7.61-7.77 (m, 4H); ¹³C NMR (75 MHz, CDCk): 19.14, 29.24, 55.17, 62.01, 62.89, 64.95, 68.61, 68.83, 69.11, 69.53,

71.55, 71.66, 71.78, 71.90, 72.05, 72.20, 72.65, 72.98, 73.05, 73.20, 74.13, 74.60, 74.75, 74.86, 75.01, 75.62, 76.18, 77.11, 77.81, 79.81, 79.53, 79.68, 79.91, 80.83, 81.52, 81.79, 81.89, 97.20, 98.29, 99.00, 99.17, 100.25, 113.89, 127.15-128.21 (multiple peaks), 133.02, 135.55, 135.47, 137.75-138.89 (multiple peaks), 159.26. HRMS (positive ion ESMS, $M+Na^+$) calcd for $C_{179}H_{189}O_{31}N_3SiNa$ 2927.2972, found 2927.2981.

(2,3,4,6-Tetra-O-benzyl-**a**-D-mannopyranosyl)- $(1\rightarrow 2)$ -(3,4-di-O-benzyl-**a**-D-mannopyranosyl)- $(1\rightarrow 2)$ -(3,4,6-tri-O-benzyl-**a**-D-mannopyranosyl)- $(1\rightarrow 6)$ -(2,3,4-tri-O-benzyl-

l-a -D-mannopyranosyl)-(1→4)-(2-azido-3,6-di-O-benzyl-2-deoxy-a -D-glucopyranos vl)- $(1\rightarrow 6)$ -2,3,4,5-tetra-O-benzyl-1-O-(4-methoxybenzyl)-D-myo-inositol The (**3d**). TBDPS protected pseudohexasaccharide (80 mg, 0.25 mmol) was dissolved in anhyd DMF (2 mL) followed by addition of benzyl bromide (90 µL, 0.66 mmol) and sodium methoxide (10 mg, 0.25 mmol). The reaction mixture was stirred at 0 °C for 1 h. quenched with methanol, diluted with EtOAc, organic layer washed with brine and HO, dried over Na₂SO₄ and concentrated. The residue was dissolved in 1.2 mL of a 1M solution of tetrabutylammonium fluoride (TBAF) in anhydrous THF and stirred at room temperature for 48 h. After completion of reaction, solvent was quickly removed under vacuum and the viscous yellow mass was purified through a small silica column (hexane-EtOAc, 70:30) to provide desired compound (87 mg, 90%) as colorless solid. TLC (hexane/EtOAc, 70:30) $R_f = 0.25$; ¹HNMR (300 MHz, CDCk): 3.15-3.85 (m, 36H), 3.96-4.88 (m, 38H), 3.73 (s, 3H), 4.94 (s, 1H), 5.17 (s, 2H), 5.29 (s, 1H), 5.71 (d, J = 3.6 Hz, 1H), 6.80 (d, 2H), 7.05-7.26 (m, 92H); ¹³C NMR (75 MHz, CDCh): 63.00, 65.96, 68.44, 68.33, 69.01, 69.25, 69.64, 70.25, 70.45, 71.57, 71.65, 71.73, 71.94, 72.00, 72.08, 72.54, 72.64, 73.07, 73.18, 74.11, 74.58, 74.65, 74.80, 74.91, 75.43, 77.10, 77.32, 77.71, 79.14, 79.62, 79.89, 80.80, 81.48, 81.78, 81.86, 97.27, 99.30, 99.31, 99.86, 100.43, 113.87, 127.21-128.17 (multiple peaks), 129.44, 138.32-138.35 (multiple peaks), 159.24; HRMS (positive ion ESMS, $M+Na^+$) calcd for $C_{170}H_{177}O_{31}N_3Na$ 2779.2264, found 2779.2273.

 $(2,3,4,6-Tetra-O-benzyl-a -D-mannopyranosyl)-(1\rightarrow 2)-(3,4-di-O-benzyl-6-O-(benzyl-2-(N-benzyloxycarbonyl)-aminoethyl-phosphonato)-a -D-mannopyranosyl)-(1\rightarrow 2)-(3,4,6-tri-O-benzyl-a -D-mannopyranosyl)-(1\rightarrow 6)-(2,3,4-tri-O-benzyl-a -D-mannopyranosyl)-(2,3,4-tri-O-benzyl-a -D-mannopyranosyl)-(2,3,4-tri-O-benzyl-a -D-mannopyranosyl)-(2,3,4-tri-O-benzyl-a -D-mannopyranosyl)-(2,3,4-tri-O-benzyl-a -D-mannopyranosyl)-(2,3,4-tri-O-benzyl-a -D-mannopyranosyl)-(2,3,4-tri-O-benzyl-a -D-mannopyranosyl)-(2,3,4-tri-O-benzyl-a -D-mannopyranosyl)-(2,3,4-tri-O-benzyl-a -D-mannopyranosyl)-(2,3,4-tri-O-benzyl-a -D-mannopyranosyl-a -D-mannopyranosyl-a -D-mannopyranosyl-a -D-mannopyranosyl-a -D-mannopyranosyl-a -D-m$

anosyl)- $(1\rightarrow 4)$ - $(2-azido-3,6-di-O-benzyl-2-deoxy-a-D-glucopyranosyl)-<math>(1\rightarrow 6)$ -2,3,4,5tetra-O-benzyl-1-O-(4-methoxybenzyl)-D-myo-inositol. Above pseudohexasaccharide **3d** (40 mg, 0.014 mmol), dried thoroughly first with co-evaporation with anhydrous toluene (three times) and then under high-vacuum for two hours, was dissolved in anhydrous CH_2Ch_2 (1 mL) and to this solution was added freshly prepared⁶ CbzNH(CH₂)₂OPOBnNiPr₂ (12 mg, 0.027 mmol) and 1H-tetrazole (2 mg, 0.027 mmol). The reaction mixture was stirred under argon at room temperature for 3 h. The reaction mixture was brought to -40 ^oC and treated with mCPBA (4 mg), stirred at -40 ^oC for 30 min and at room temp for 1 h. The reaction was now quenched with saturated aqueous NaHCO₃ solution, diluted with CH₂Cb, the organic phase was dried (Na₂SO₄), concentrated and the residue was purified on a small silica column (EtOAc:Hexane:Et₃N; 1:3:0.1) to give desired phosphorylated product (27 mg, 60%) as a diastereoisomeric mixture. TLC (hexane/EtOAc, 60:40) $R_{f} = 0.35/0.37$; ¹HNMR (300 MHz, CDC_h): 3.18-5.15 (m, 90H), 5.52 (d, 1H), 6.80 (d, 2H), 7.09-7.40 (m, 102H, ArH); ¹³C NMR (75 MHz, CDCh): 65.19, 66.54, 66.79, 68.83, 69.69, 71.96, 72.19, 72.81, 73.01, 74.15, 74.48, 74.87, 75.21, 76.45, 77.35, 78.59, 79.58, 79.99, 80.91, 95.13, 98.89, 99.12, 100.07, 113.87, 127.04-128.37 (multiple peaks), 129.44, 137.59-138.67 (multiple peaks), 156.33, 159.24; ³¹P NMR (125 MHz): -0.61, 0.84; HRMS (positive ion ESMS, M+Na⁺) calcd for C₁₈₇H₁₉₅O₃₆N₄PNa 3126.3186, found 3126.3192.

(2,3,4,6-Tetra-*O*-benzyl-a -D-mannopyranosyl)-(1 \rightarrow 2)-(3,4-di-*O*-benzyl-6-*O*-(benzyl-2-(N-benzyloxycarbonyl)-aminoethyl-phosphonato)-a -D-mannopyranosyl)-(1 \rightarrow 2)-(3,4,6-tri-*O*-benzyl-a -D-mannopyranosyl)-(1 \rightarrow 6)-(2,3,4-tri-*O*-benzyl-a -D-mannopyr anosyl)-(1 \rightarrow 4)-(2-azido-3,6-di-*O*-benzyl-2-deoxy-a -D-glucopyranosyl)-(1 \rightarrow 6)-2,3,4,5tetra-*O*-benzyl-1-*O*-(2-hexadecanoyl-1-*O*-octadecyl-sn-glyceryl-phosphonato)-D*myo*-inositol (Fully-protected GPI anchor). The above compound (27 mg, 8.7 µmol) dissolved in a solution of CH₃CN/ toluene/water (1 mL, 91:5:4) was treated with CAN (25 mg, 45 µmol) was at 0 ^oC, and the solution was stirred at for 30 min at the same temp and at room temperature for 1 h. the reaction mixture was diluted with CH₂Cl₂, washed with saturated NAHCO₃ solution and the combined organic layer was dried over Na₂SO₄. Silica column (toluene/acetone, 1:1) afforded PMB deprotected phosphohexasaccahride (20 mg, 77%). The above compound (17 mg, 5.7 μ mol), and freshly prepared 2-*O*-octadecanoyl-1-*O*-octadecyl-*sn*-glyceryl-*H*-phosphonate (**2**, 30 mg, 44 μ mol) were dried by evaporation with anhyd pyridine three times, and dissolved in anhyd pyridine (0.4 mL). This was followed by addition of pivaloyl chloride (9.6 μ L, 80 μ mol). After stirring at room temperature for 30 min, the reaction was treated with an iodine solution (2 equiv, 20 mg iodine in pyridine-water, 2.45:0.05) and the mixture was further stirred for 25 min. The reaction was diluted with CHCl₃ and organic layer washed with 5% sodium bisulfite solution. The organic layer was dried over Na₂SO₄, concentrated and purified on a silica column using 5% MeOH-CH₂Cl₂ (with 1% triethylamine) solvent system, providing the desired phospholipidated fully protected GPI-anchor (12 mg, 55%). ¹H NMR (300 MHz, CDCl₃): 0. 87 (t, 6H), 1.24 (m, 58H), 1.43 (m, 2H), 1.51-1.65 (m, 4H), 2.80-5.85 (m, 89H), 7.0-7.80 (m, 100H); HRMS (ESMS, M+Na⁺) calcd for C₂₁₈H₂₆₄O₄₁N₄P₂Na 3678.8069, found 3678.8021.

a -D-mannopyranosyl)-(1→2)-(6-*O*-(aminoethylphosphonato)-**a** -D-mannopyranos syl)-(1→2)-**a** -D-mannopyranosyl)-(1→6)-**a** -D-mannopyranosyl)-(1→4)-(2-amino-2deoxy-**a** -D-glucopyranosyl)-(1→6)-1-*O*-(2-hexadecanoyl-1-*O*-octadecyl-sn-glycerylphosphonato)-D-myo-inositol (1). The protected GPI-anchor (12 mg, 3.2 µmol) and the catalyst 20% Pd(OH)₂ (25 mg) were dissolved in a solvent mixture of MeOH (1 mL), CH₂Cl₂ (1 mL) and H₂O (0.05 mL). The residual and dissolved air from the flask was removed by repeated evacuations by suction. The reaction mixture was then stirred under positive hydrogen atmosphere for 48 h. After completion of reaction, the mixture was filtered through a small celite pad, which was washed several times with the solvent mixture, and concentrated under reduced pressure to provide desired GPI-anchor 1 (4.2 mg, 73%). ¹H NMR (300 MHz, CD₃OD-CDCl₃-D₂O) 0.87-1.00 (m, 6H), 1.16-2.35 (m, 66H), 2.63-4.28 (m, 45H), 4.76 (1H), 5.10 (br s, 2H), 5.18 (br s, 1H), 5.40 (br s, 1H); MS (ESMS, M+H+Na) calcd for C₇₇H₁₄₇O₃₉N₂P₂Na 1808.8954, found 1808.8990.

References:

- 1. D. J. R. Massy and P. Wyss, Helv. Chim. Acta, 1990, 73, 1037-1057.
- 2. C. Murakata and T. Ogawa, *Carbohydr. Res.*, 1992, 234, 75-95.
- 3. T. G. Mayer and R. R. Schmidt, Eur. J. Org. Chem., 1999, 3, 1153-1165.
- 4. K. Pekari, D.Tailler, R. Weingart and R. R. Schmidt, J. Org. Chem., 2001, 66, 7432-7442.
- R. Madsen, U. E. Udodong, C. Roberts, D. R. Mootoo, P. Konradsson and B. Fraser-Reid, J. Am. Chem. Soc., 1995, 117, 1554-1565.
- 6. A. S. Campbell and B. Fraser-Reid, *Bioorg. Med. Chem.*, 1994, 2, 1209-1219.